181 BIBLIOGRAFIA ESSENZIALE

1. Standard Italiani per la cura del diabete mellito https://aemmedi.it/wp-content/uploads/2009/06/AMD-Standard-unico1.pdf. Last accessed on June, 11st 2021.

2. NICE Guideline 2015 https://www.nice.org.uk/guidance/ng17 Last accessed on June, 11st 2021.

3. Standards of Medical Care in Diabetes - 2021. Diabetes care 2021; 44(Suppl 1).

4. Shafie AA, Ng CH, Tan YP, Chaiyakunapruk N. Systematic Review of the Cost Effectiveness of Insulin Analogues in Type 1 and Type 2 Diabetes Mellitus. Pharmacoeconomics. 2017 Feb;35:141-162.

5. https://www.siditalia.it/ricerca/centro-studi-e-ricerche/22-ricerca/centro-studi-e-ricerche/68-arnodiabete.Last accessed on June, 11st 2021.

6. https://aemmedi.it/annali-amd/. Last accessed on June, 11st 2021.

7. Vargas-Uricoechea H. Efficacy and Safety of Insulin Glargine 300 U/mL versus 100 U/mL in Diabetes Mellitus: A Comprehensive Review of the Literature. J Diabetes Res. 2018:2052101.

8. Zhang XW, Zhang XL, Xu B, Kang LN. Comparative safety and efficacy of insulin degludec with insulin glargine in type 2 and type 1 diabetes: a meta-analysis of randomized controlled trials. Acta Diabetol. 2018

;55:429-441.

9. Gschwend MH, Aagren M, Valentine WJ. Cost-effectiveness of insulin detemir compared with neutral protamine Hagedorn insulin in patients with type 1 diabetes using a basal-bolus regimen in five European countries. J Med Econ. 2009;12:114-23.

10. Pala L, Dicembrini I, Mannucci E. Continuous subcutaneous insulin infusion vs modern multiple injection regimens in type 1 diabetes: an updated meta-analysis of randomized clinical trials. Acta Diabetol.

2019;56:973-980.

182

11. Valentine WJ, Van Brunt K, Boye KS, Pollock RF. Treating Type 1 Diabetes Mellitus with a Rapid-Acting Analog Insulin Regimen vs. Regular Human Insulin in Germany: A Long-Term Cost-Effectiveness Evaluation. Appl Health Econ Health Policy. 2018;16:357-366.

12. De Berardis G, Scardapane M, Lucisano G, Abbruzzese S, Bossi AC, Cipponeri E, D'Angelo P, Fontana L, Lancione R, Marelli G, Sciangula L, Nicolucci A. Efficacy, safety and acceptability of the new pen needle 34G × 3.5 mm: a crossover randomized non-inferiority trial; AGO 02 study. Curr Med Res Opin 2018;34:1699-1704.

13. Valentini M, Scardapane M, Bondanini F, Bossi A, Colatrella A, Girelli A, Ciucci A, Leotta S, Minotti E, Pasotti F, Pesenti A, Rocca L, Sciangula L, Vavassori E, Nicolucci A. Efficacy, safety and acceptability of the new pen needle 33G × 4 mm. AGO 01 study. Curr Med Res Opin 2015;31:487-92.

14. Sun L, Ren X, Zhu S, Liu Y, Chen Y, Sun J, Chen B, Sun S, Wang R. Health Economics Evaluation for Insulin Injection Pen-Needle with Different Lengths in Patients With Diabetes in China. Value Health 2014;17:A342.

15. Barnard KD, Lloyd CE, Skinner TC. Systematic literature review: quality of life associated with insulin pump use in Type 1 diabetes. Diabet Med 2007;24:607-17.

16. Doubova SV, Roze S, Ferreira-Hermosillo A, Pérez-Cuevas R, Gasca-Pineda R, Barsoe C, Baran J, Ichihara B, Gryzbowski E, Jones K, Valencia JE. Cost-effectiveness of the use of the continuous subcutaneous insulin infusion pump versus daily multiple injections in type 1 diabetes adult patients at the Mexican Institute of Social Security. Cost Eff Resour Alloc 2019;17:19.

17. Heller S, White D, Lee E, Lawton J, Pollard D, Waugh N, Amiel S, Barnard K, Beckwith A, Brennan A, Campbell M, Cooper C, Dimairo M, Dixon S, Elliott J, Evans M, Green F, Hackney G, Hammond P, Hallowell N, Jaap A, Kennon B, Kirkham J, Lindsay R, Mansell P, Papaioannou D, Rankin D, Royle P, Smithson WH, Taylor C. A cluster randomised trial, cost-effectiveness analysis and psychosocial evaluation of insulin pump therapy compared with multiple injections during flexible intensive insulin therapy for type 1 diabetes: the REPOSE Trial. Health Technol Assess 2017;21:1-278.

183

18. Roze S, Smith-Palmer J, Valentine W, de Portu S, Nørgaard K, Pickup JC. Cost-effectiveness of continuous subcutaneous insulin infusion versus multiple daily injections of insulin in Type 1 diabetes: a systematic review. Diabet Med 2015;11:1415-24.

19. Kropff J, Del Favero S, Place J, et al. 2 month evening and night closed-loop glucose control in patients with type 1 diabetes under free-living conditions: a randomised crossover trial. Lancet Diabetes Endocrinol2015;3: 939-947.

20. Thabit H, Tauschmann M, Allen JM, et al. Home use of an artificial beta cell in type 1 diabetes. N Engl J Med 2016;373:2129-2140.

21. Tauschmann M, Thabit H, Bally L, et al. Closed-loop insulin delivery in suboptimally controlled type 1 diabetes: a multicentre, 12-week randomised trial. Lancet 2018; 392:1321-1329.

22. Brown SA, Kovatchev BP, Raghinaru D, Lum JW, Buckingham BA, Kudva YC, Laffel LM, Levy CJ, Pinsker JE, Wadwa RP, Dassau E, Doyle FJ 3rd, Anderson SM, Church MM, Dadlani V, Ekhlaspour L, Forlenza GP, Isganaitis E, Lam DW, Kollman C, Beck RW; iDCL Trial Research Group. Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes. N Engl J Med 2019;18:1707-1717.

23. Bergenstal RM, Klonoff DC, Garg SK, Bode BW, Meredith M, Slover RH, Ahmann AJ, Welsh JB, Lee SW, Kaufman FR; ASPIRE In-Home Study Group. Threshold-based insulin-pump interruption for reduction of hypoglycemia. N Engl J Med. 2013 Jul 18;369(3):224-32.

24. Ly TT, Nicholas JA, Retterath A, Lim EM, Davis EA, Jones TW. Effect of sensor-augmented insulin pump therapy and automated insulin suspension vs standard insulin pump therapy on hypoglycemia in patients with type 1 diabetes: a randomized clinical trial. JAMA 2013;12:1240-7.

25. Nicolucci A, Rossi MC, D'Ostilio D, Delbaere A, de Portu S, Roze S. Cost-effectiveness of sensor-augmented pump therapy in two different patient populations with type 1 diabetes in Italy. Nutr Metab Cardiovasc Dis. 2018;7:707-715.

184

26. Jendle J, Pöhlmann J, de Portu S, Smith-Palmer J, Roze S. Cost-Effectiveness Analysis of the MiniMed 670G Hybrid Closed-Loop System Versus Continuous Subcutaneous Insulin Infusion for Treatment of Type 1 Diabetes. Diabetes Technol Ther. 2019;3:110-118.

27. Pease A, Lo C, Earnest A, Kiriakova V, Liew D, Zoungas S. The Efficacy of Technology in Type 1 Diabetes: A Systematic Review, Network Meta-analysis, and Narrative Synthesis. Diabetes Technol Ther 2020;22:411-421.

28. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-986.

29. JM Lachin, TJ Orchard, DM Nathan, for the DCCT/EDIC Research Group. Update on Cardiovascular Outcomes at 30 Years of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study. Diabetes Care 2014;37:39-43.

30. Gomez AM et al. "Clinical and economic benefits of integrated pump/CGM technology therapy in patients with type 1 diabetes in Colombia." Endocrinol Nutr 63(9): 466-474.

31. Wan EYF et al. "Ten-year risk prediction models of complications and mortality of Chinese patients with diabetes mellitus in primary care in Hong Kong: a study protocol." BMJ Open 2018;8(10): e023070.

32. Conget I et al. "Cost-effectiveness analysis of sensor-augmented pump therapy with low glucose-suspend in patients with type 1 diabetes mellitus and high risk of hypoglycemia in Spain." Endocrinol Diabetes Nutr 2018;65(7): 380-386.

33. Jendle J et al. "Cost-Effectiveness Analysis of Sensor-Augmented Insulin Pump Therapy with Automated Insulin Suspension Versus Standard Insulin Pump Therapy in Patients with Type 1 Diabetes in Sweden." Diabetes Ther 2017;8(5): 1015-1030.

185

34. Ly TT et al.. "A cost-effectiveness analysis of sensor-augmented insulin pump therapy and automated insulin suspension versus standard pump therapy for hypoglycemic unaware patients with type 1 diabetes."

Value in Health 2014;17(5): 561-569.

35. Riemsma R et al. "Integrated sensor-augmented pump therapy systems [the MiniMed® Paradigm™ Veo system and the Vibe™ and G4® PLATINUM CGM (continuous glucose monitoring) system] for managing blood glucose levels in type 1 diabetes: a systematic review and economic evaluation." Health Technol Assess 2016;20(17): v-xxxi, 1-251.

36. Roze Set al "Cost-Effectiveness of Sensor-Augmented Pump Therapy with Low Glucose Suspend Versus Standard Insulin Pump Therapy in Two Different Patient Populations with Type 1 Diabetes in France."

Diabetes Technol Ther 2016;18(2): 75-84.

37. Roze S et al. "Cost-effectiveness of sensor-augmented insulin pump therapy vs continuous subcutaneous insulin infusion in patients with type 1 diabetes in the Netherlands." Clinicoecon Outcomes Res 2019;11: 73-82.

38. Roze S et al. "Cost-Effectiveness of Sensor-Augmented Insulin Pump Therapy Versus Continuous Insulin Infusion in Patients with Type 1 Diabetes in Turkey." Diabetes Technol Ther 2019;21(12): 727-735.

39. Roze S et al. "Long-term health economic benefits of sensor-augmented pump therapy vs continuous subcutaneous insulin infusion alone in type 1 diabetes: a U.K. perspective." J Med Econ 2016;19(3): 236-242.

40. Roze S et al. "Health-economic analysis of real-time continuous glucose monitoring in people with Type 1 diabetes." Diabet Med 2015;32(5): 618-626.

41. Roze S et al. "Cost-effectiveness of sensor-augmented pump therapy versus standard insulin pump therapy in patients with type 1 diabetes in Denmark." Diabetes Res Clin Pract 2017;128: 6-14.

186